This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Zanett, Novell: Early Volume Plays

NEW YORK (TheStreet) -- Several stocks trading near $5 were poised to move on above-average volume during Monday's session.

Zanett (ZANE) slipped 5 cents, or 2%, to $2.53 in early trading after the company said it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq. This comes after the stock finished at or above $1 for 10 consecutive business days from March 4 to March 17. The 50-day average daily volume for Zanett is 1.07 million.

Novell (NOVL) jumped by 29 cents, or 5.1%, to $5.93 shortly after the opening bell Monday after the software company rejected an unsolicited bid from Elliott Associates as "inadequate." Elliott had offered the conditional proposal to acquire Novell for $5.75 per share. Novell added that it believes that an exploration of alternatives is in the best interests of the company and its stockholders. The 50-day average daily volume for Novell is 9.5 million.

BioDelivery Sciences International (BDSI) rose by 18 cents, or 4.4%, to $4.18 at the start of trading after the company announced the positive outcome of a meeting with the Food and Drug Administration on the development program for BEMA Granisetron, the company's potential treatment for the prevention of nausea and vomiting associated with cancer therapy. The FDA concurred with BioDelivery's plans to pursue a development program based on clinical pharmacokinetic data for a New Drug Application (NDA). The 50-day average daily volume for BioDelivery is 90,000.

PharmAthene (PIP) dropped by 21 cents, or 13.3%, to $$1.50 after the biodefense company said it is pursuing various options to move forward under a contract modification announced on Feb. 23 to its existing contract with the Biomedical Advanced Research and Development Authority for the research and development of SparVax pending a final ruling under the protest. The company said it is confident that the protest is without merit and that the contract modification will be upheld. The three-month average daily volume for PharmAthene is 719,000, according to Yahoo! Finance.

-- Written by Robert Holmes in Boston.

Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of TheStreet.com on Facebook.

Stock quotes in this article: ZANE, NOVL 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,509.03 +7.38 0.04%
S&P 500 1,877.27 +1.88 0.10%
NASDAQ 4,143.1710 +16.2040 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs